Float Short %

26.31

Margin Of Safety %

Put/Call OI Ratio

0.29

EPS Next Q Diff

-0.16

EPS Last/This Y

-1.37

EPS This/Next Y

-0.59

Price

26.01

Target Price

89.88

Analyst Recom

1.24

Performance Q

-6.24

Relative Volume

Beta

0.75

Ticker: VKTX

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2025-07-28	VKTX	33.19	0.29	0.30	227105
2025-07-29	VKTX	32.89	0.29	0.26	234906
2025-07-30	VKTX	33.7	0.29	0.25	237193
2025-07-31	VKTX	32.58	0.29	0.18	240928
2025-08-01	VKTX	32.67	0.28	0.36	245296
2025-08-04	VKTX	34	0.27	0.24	235200
2025-08-05	VKTX	34.02	0.27	0.22	245461
2025-08-06	VKTX	31.89	0.27	0.27	249584
2025-08-07	VKTX	35.54	0.27	0.16	258260
2025-08-08	VKTX	37.88	0.26	0.16	268607
2025-08-11	VKTX	38.21	0.27	0.28	264667
2025-08-12	VKTX	39.88	0.27	0.26	284131
2025-08-13	VKTX	41.18	0.27	0.20	291618
2025-08-14	VKTX	40.24	0.28	0.30	298918
2025-08-15	VKTX	40.03	0.30	0.19	305371
2025-08-18	VKTX	42.13	0.23	0.43	232622
2025-08-19	VKTX	24.33	0.26	0.36	256618
2025-08-20	VKTX	25.73	0.31	0.30	306830
2025-08-21	VKTX	25.66	0.30	0.26	317153
2025-08-22	VKTX	26.03	0.29	0.23	320370
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-07-28	VKTX	33.26	-211.8	-87.0	-2.40
2025-07-29	VKTX	32.91	-211.8	-96.9	-2.40
2025-07-30	VKTX	33.71	-209.3	-110.1	-2.39
2025-07-31	VKTX	32.57	-209.3	-86.9	-2.39
2025-08-01	VKTX	32.68	-209.3	-101.8	-2.39
2025-08-04	VKTX	33.98	-209.3	-116.3	-2.39
2025-08-05	VKTX	34.03	-209.3	-101.0	-2.39
2025-08-06	VKTX	31.89	-209.3	-75.4	-2.39
2025-08-07	VKTX	35.56	-209.3	-147.0	-2.39
2025-08-08	VKTX	37.89	-209.3	-126.1	-2.39
2025-08-11	VKTX	38.21	-209.3	-103.7	-2.39
2025-08-12	VKTX	39.86	-209.3	-117.3	-2.37
2025-08-13	VKTX	41.27	-211.8	-113.9	-2.37
2025-08-14	VKTX	40.27	-211.8	-91.2	-2.38
2025-08-15	VKTX	40.03	-211.8	-98.4	-2.38
2025-08-18	VKTX	42.15	-211.8	-120.6	-2.38
2025-08-19	VKTX	24.36	-211.8	58.7	-2.38
2025-08-20	VKTX	25.68	-211.8	-124.6	-2.38
2025-08-21	VKTX	25.65	-211.8	-99.7	-2.38
2025-08-22	VKTX	26.01	-211.8	-106.4	-2.38
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-07-28	VKTX	-1.01	-4.88	26.22
2025-07-29	VKTX	-1.01	-4.88	26.22
2025-07-30	VKTX	-1.01	-4.88	26.22
2025-07-31	VKTX	-1.01	-4.88	26.22
2025-08-01	VKTX	-1.01	-4.88	26.22
2025-08-04	VKTX	-1.01	-4.98	26.22
2025-08-05	VKTX	-1.01	-4.98	26.22
2025-08-06	VKTX	-1.01	-4.98	26.22
2025-08-07	VKTX	-1.01	-4.98	26.22
2025-08-08	VKTX	-1.01	-4.98	26.22
2025-08-11	VKTX	-1.01	-5.04	26.22
2025-08-12	VKTX	-1.01	-5.04	26.31
2025-08-13	VKTX	-1.01	-5.04	26.31
2025-08-14	VKTX	-1.01	-5.04	26.31
2025-08-15	VKTX	-1.01	-5.04	26.31
2025-08-18	VKTX	-1.01	-2.27	26.31
2025-08-19	VKTX	-1.01	-2.27	26.31
2025-08-20	VKTX	-1.01	-2.27	26.31
2025-08-21	VKTX	-1.01	-2.27	26.31
2025-08-22	VKTX	-1.01	-2.27	26.31
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-0.58

Avg. EPS Est. Current Quarter

-0.69

Avg. EPS Est. Next Quarter

-0.74

Insider Transactions

-1.01

Institutional Transactions

-2.27

Beta

0.75

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

73.8

Max Drawdown 5-Year %

-78.9

Target Price

89.88

P/E

Forward P/E

PEG

P/S

P/B

3.67

P/Free Cash Flow

EPS

-1.53

Average EPS Est. Cur. Y

-2.38

EPS Next Y. (Est.)

-2.97

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

-46.3

Return on Equity vs Industry %

-33.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.53

EBIT Estimation

-106.4

Viking Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 48

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.

stock quote shares VKTX – Viking Therapeutics, Inc. Stock Price stock today

news today VKTX – Viking Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VKTX – Viking Therapeutics, Inc. yahoo finance google finance

stock history VKTX – Viking Therapeutics, Inc. invest stock market

stock prices VKTX premarket after hours

ticker VKTX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VKTX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y